The agreement was signed in line with the objectives of the Plan México, aimed at enhancing the country’s health capabilities, fostering innovation, and moving towards greater health sovereignty through the development of infrastructure and talent.
MEXICO CITY (apro) – The Ministry of Health (SSA), Biological and Reagent Laboratories of Mexico, S.A. de C.V. (Birmex) and Pfizer, S.A. de C.V. entered into a Memorandum of Understanding (MOU) to “enhance the country’s capabilities in the access, production, and development of messenger RNA (mRNA) technologies, thereby strengthening national health sovereignty.”
According to the agency led by David Kershenobich, a key aspect of this partnership is the mRNA technology transfer project for vaccines, which “would boost the country’s industrial and logistical capabilities in this field.”
One month ago, on February 9, the SSA and Birmex signed an agreement with the firms Liomont and Moderna for the same purpose: the production of mRNA vaccines and the development of biologicals targeting other diseases.
At the signing of the latest memorandum with pharmaceutical company Pfizer, the head of the SSA emphasized that “Mexico must enhance its capacities to produce and manage vaccines. The pandemic has taught us that having our own technological capabilities is crucial to protect the health of our population.”
The new partnership also opens opportunities to expand clinical research in Mexico and promote scientific training and medical education programs that will contribute to the development of national talent in the biomedical field.
The agreement was signed as part of the Plan México objectives, which are focused on enhancing the country’s health capabilities, driving innovation, and progressing towards greater health sovereignty through the development of infrastructure and talent.
By signing, the SSA, Birmex, and Pfizer reaffirmed their “commitment to work together to enhance the country’s capabilities in health research and innovation, for the benefit of the Mexican population.”
The Memorandum was signed by the Secretary of Health, David Kershenobich; the General Director of BIRMEX, Carlos Alberto Ulloa Pérez; and by the President and General Director of Pfizer, S.A. de C.V., Juan Luis Morell Villarias.
